J. Vaage et al., INHIBITION OF MOUSE MAMMARY-CARCINOMA DEVELOPMENT WITH DOXORUBICIN INLIPOSOMES, International journal of cancer, 75(1), 1998, pp. 158-159
Monthly treatments with intravenous doxorubicin encapsulated in long c
irculating, sterically stabilized liposomes delayed the appearance of
primary mammary carcinomas and reduced the final incidence from 49 in
50 untreated mice to 46 in 87 treated mice. No toxic side effects of t
he treatments were observed. (C) 1998 Wiley-Liss, Inc.